Hormone Therapy and Breast Cancer Risk: What Can Our Genetics Tell Us?

curve-up2
10 26 Header image

Every October, Breast Cancer Awareness Month brings renewed attention to breast cancer risk, prevention, and early detection. But for women navigating menopause, another question often comes up:

Does menopausal hormone therapy (MHT) increase the risk of breast cancer?

The answer isn’t always straightforward. Doctors consider individual risk factors when deciding whether MHT is appropriate, yet women with similar medical histories may face different risks.

Researchers are now investigating whether inherited genetic variants could help explain these differences and eventually help women and their doctors make more informed MHT treatment decisions.

Confusion about MHT and breast cancer risk

Many women are confused about MHT and breast cancer risk. Much of the confusion surrounding MHT dates back to 2002, when the Women’s Health Initiative (WHI) stopped a clinical trial early after finding increased risks of breast cancer and other negative health effects among women taking combined hormone therapy.1 The findings led to widespread concern, new FDA warnings,2 and a sharp decline in MHT use.

Since then, additional research has provided a more nuanced understanding of the benefits and risks of MHT. In 2026, the FDA revised “black box warnings” for certain hormone therapy products, and the American College of Obstetricians & Gynecologists issued updated recommendations supporting hormonal and nonhormonal treatments for menopause symptoms.3,4 While MHT can benefit many women, understanding individual risk remains essential.

To learn more about MHT and breast cancer risk, visit Breastcancer.org.

Weighing the Benefits and Risks of MHT

MHT can effectively relieve menopause symptoms and help prevent bone loss and protect both the brain and heart, but it may increase breast cancer risk or clotting and isn’t appropriate for everyone.

Doctors consider factors including age, time at menopause, medical history, cardiovascular health, and personal or family history of breast cancer when evaluating its benefits and risks.5 The type of hormone therapy, dose, and method of delivery also matter, particularly when considering breast cancer risk.5

Yet research findings on how these factors influence risk can add another layer of confusion.

What research says about MHT and breast cancer risk

Research has shown that the relationship between MHT and breast cancer risk is complex. Studies have reported differing findings about the risks associated with estrogen-only therapy and estrogen combined with progestogens.6-11

These differences may reflect the types of hormones used, duration of treatment, and populations studied, as well as differences in study design. Because this research has some contradictory results, it does not cleanly help inform treatment decisions, and it doesn’t fully explain why individual women may face different risks.

Researchers are now exploring whether inherited genetics could provide another piece of the puzzle.

A link between genetics, estrogen, and breast cancer risk: the KRAS-variant

Researchers have identified a possible connection between estrogen, breast cancer risk, and an inherited genetic variant called the KRAS-variant.

In a 2015 study, Dr. Joanne Weidhaas and colleagues found that there was an association between the KRAS-variant and estrogen and breast cancer risk:12

  • Women with the KRAS-variant who discontinued MHT were more likely to develop triple-negative breast cancer, an aggressive form of the disease.
  • Women with the KRAS-variant and breast cancer were more likely to have had their ovaries removed—a procedure that causes an abrupt drop in estrogen levels.
  • Women with the KRAS-variant with breast cancer versus KRAS-variant women without breast cancer were more likely to be thin, leading to lower circulating estrogen.
  • In laboratory experiments, removing estrogen caused breast cells carrying the KRAS-variant to develop cancer-like changes, unlike breast cells without the KRAS-variant.

To learn more about the KRAS-variant and other microRNA-based inherited genetic variants, read our educational post on Genetics & Cancer.

Together, these findings suggest that estrogen may play a protective role against developing breast cancer in women with the KRAS-variant and that for these women a sudden drop in estrogen could be associated with increased breast cancer risk.

Could microRNA variants hold clues to breast cancer risk with MHT?

Building on this earlier research, Dr. Joanne Weidhaas and colleagues at UCLA are investigating whether other inherited microRNA variants could help predict who might be at an increased or decreased breast cancer risk with the use of MHT.

Their recent study, scheduled to be presented at the 2026 San Antonio Breast Cancer Symposium (SABCS) in December, presents the preliminary findings.

While more research is needed, the long-term goal is important: understanding how a woman’s genetics may influence her individual breast cancer risk as it relates to MHT use could eventually enable women and their doctors to make more informed decisions about taking menopausal hormone therapy.


References

  1. https://jamanetwork.com/journals/jama/fullarticle/195120
  2. https://www.nytimes.com/2003/01/09/us/fda-orders-warning-on-all-estrogen-labels.html
  3. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
  4. https://www.acog.org/news/2026/10/acog-expands-recommendations-for-management-of-menopause-symptoms/
  5. https://www.mayoclinic.org/diseases-conditions/menopause/in-depth/hormone-therapy/art-20046372
  6. https://jamanetwork.com/journals/jama/fullarticle/2768806
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC6891893/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC2211383/
  9. https://www.nature.com/articles/s41416-024-02590-1
  10. https://pubmed.ncbi.nlm.nih.gov/38469634/
  11. https://www.bmj.com/content/371/bmj.m3873
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC4614527/

STAY INFORMED

Join our mailing list for news and updates about how our continuing genetic research is advancing cancer treatment and prevention!

SHARE   —

mk-home-hero-bottom

Leave a Reply

Your email address will not be published. Required fields are marked *